Guidant acquires CardioThoracic in $313 million stock swap
This article was originally published in Clinica
Guidant is to acquire CardioThoracic Systems (CTS) in a stock swap valued at $313 million. The move ends speculation of a bidding war for the minimally-invasive coronary surgery company and leaves shareholders disappointed that the management of the Cupertino, California-based CTS could only gain a 50c premium per share on its trading price last week of $19.00.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.